Kidney function monitoring and trajectories in patients with atrial fibrillation

[1] Healey JS(2016)Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study Lancet 388 1161-1169

[2] Oldgren J(2016)Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment Eur J Heart Fail 18 1162-1171

[3] Ezekowitz M(2020)Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation Heart 106 358-364

[4] Zhu J(2017)Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction J Am Coll Cardiol 69 2779-2790

[5] Pais P(2013)KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease Kidney Int Suppl 3 1-150

[6] Wang J(2020)The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation Can J Cardiol 36 1847-1948

[7] Hawkins NM(2009)Overview of the Alberta Kidney Disease Network BMC Nephrol 10 30-1415

[8] Jhund PS(2019)Empirical insights when defining the population burden of atrial fibrillation and oral anticoagulation utilization using administrative data Can J Cardiol 35 1412-S209

[9] Pozzi A(2018)Chronic kidney disease in diabetes Can J Diabetes 42 Suppl 1 S201-S98

[10] O'Meara E(2017)10. Microvascular Complications and Foot Care Diabetes Care 40 S88-2493

[1] Healey JS(2016)Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study Lancet 388 1161-1169

[2] Oldgren J(2016)Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment Eur J Heart Fail 18 1162-1171

[3] Ezekowitz M(2020)Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation Heart 106 358-364

[4] Zhu J(2017)Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction J Am Coll Cardiol 69 2779-2790

[5] Pais P(2013)KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease Kidney Int Suppl 3 1-150

[6] Wang J(2020)The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation Can J Cardiol 36 1847-1948

[7] Hawkins NM(2009)Overview of the Alberta Kidney Disease Network BMC Nephrol 10 30-1415

[8] Jhund PS(2019)Empirical insights when defining the population burden of atrial fibrillation and oral anticoagulation utilization using administrative data Can J Cardiol 35 1412-S209

[9] Pozzi A(2018)Chronic kidney disease in diabetes Can J Diabetes 42 Suppl 1 S201-S98

[10] O'Meara E(2017)10. Microvascular Complications and Foot Care Diabetes Care 40 S88-2493